Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer

Clinical Ovarian Cancer

Volumn 3, Issue 2, 2010, Pages 81-97

  Thigpen, J Tate ^a   Alberts, David ^b   Birrer, Michael ^c   Copeland, Larry ^d   Coleman, Robert L ^e   Markman, Maurie ^f   Bast Jr , Robert C ^e   Eisenhauer, Eric L ^d   Fleming, Gini ^g   Fracasso, Paula M ^h   Gershenson, David M ^e   Herzog, Thomas ⁱ   Monk, Bradley J ^j   Ozols, Robert F ^k   Rustin, Gordon ^l   Brady, Mark F ^m   Shrader, Marissa ⁿ   Ranganathan, Aarati ⁿ  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f CANCER TREATMENT CENTERS OF AMERICA   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ St Joseph's Hospital ^*  (United States)

^j CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l MOUNT VERNON HOSPITAL   (United Kingdom)

^m Buffalo Niagara Enterprise   (United States)

ⁿ Physicians' Education Resource   (United States)

more..

Author keywords

Bevacizumab; CA 125; Cediranib; Pazopanib

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 IODO 3 NITROBENZAMIDE; AFLIBERCEPT; AGO 14699; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; HUMAN EPIDIDYMIS PROTEIN 4; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NOTCH RECEPTOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SELUMETINIB; TOPOTECAN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VELIPARIB;

BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; DIET; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LYMPHADENECTOMY; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PHYSICAL ACTIVITY; PROTEOMICS; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THROMBOEMBOLISM; TRANSVAGINAL ECHOGRAPHY; WOUND HEALING;

EID: 79951935624     PISSN: 19414390     EISSN: 19414404     Source Type: Journal    
DOI: 10.3816/COC.2010.n.015     Document Type: Review

References (157)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009.
2. Thomson CA, Alberts DS. Diet and survival after ovarian cancer: where are we and what's next? J Am Diet Assoc 2010;110:366-8.
3. Dolecek TA, McCarthy BJ, Joslin CE, et al. Prediagnosis food patterns are associated with length of survival from epithelial ovarian cancer. J Am Diet Assoc 2010;110:369-82.
4. Huncharek M, Kupelnick B. Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis of 6, 689 subjects from 8 observational studies. Nutr Cancer 2001;40:87-91. (Pubitemid 34274912)
5. Pan SY, Ugnat AM, Mao Y, et al. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1521-7. (Pubitemid 39202321)
6. Prentice RL, Thomson CA, Caan B, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 2007;99:1534-43. (Pubitemid 351767234)
7. Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: The Iowa Women's Health Study. Cancer 2004;100:1515-21. (Pubitemid 38366856)
8. Lahmann PH, Friedenreich C, Schulz M, et al. Physical activity and ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2009;18:351-4.
9. Leitzmann MF, Koebnick C, Moore SC, et al. Prospective study of physical activity and the risk of ovarian cancer. Cancer Causes Control 2009;20:765-73.
10. Pan SY, Ugnat AM, Mao Y. Physical activity and the risk of ovarian cancer: a case-control study in Canada. Int J Cancer 2005;117:300-7. (Pubitemid 41377451)
11. Lacey JV, Jr, Leitzmann M, Brinton LA, et al. Weight, height, and body mass index and risk for ovarian cancer in a cohort study. Ann Epidemiol 2006;16:869-76. (Pubitemid 44855651)
12. Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. Cancer 2009;115:812-22.
13. Clinicaltrials.gov [Web site]. Can diet and physical activity modulate ovarian and primary peritoneal cancer progression-free survival? Available at: http://www.clinicaltrials.gov/ct2/show/NCT00719303. Accessed April 12, 2010.
14. Moore RG, MacLaughlan S, Bast RC, Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 2010;116:240-5.
15. Chu CS, Rubin SC. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 2006;20:307-20. (Pubitemid 43380602)
16. Joyner AB, Runowicz CD. Ovarian cancer screening and early detection. Womens Health (Lond Engl) 2009;5:693-9.
17. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919-26. (Pubitemid 46657391)
18. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21:206s-10s.
19. Lu KH, Skates S, Bevers TB, et al. A prospective U. S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol 2010;28(15 suppl): 390s (abstract 5003).
20. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
21. Kim G, Minig L, Kohn EC. Proteomic profiling in ovarian cancer. Int J Gynecol Cancer 2009;19(Suppl 2): S2-6.
22. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7. (Pubitemid 34178440)
23. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72. (Pubitemid 351302552)
24. Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-66.
25. Cass I, Karlan BY. Ovarian cancer symptoms speak out-but what are they really saying? J Natl Cancer Inst 2010;102:211-2.
26. Hamilton W, Peters TJ, Bankhead C, et al. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009;339: b2998.
27. Lurie G, Thompson PJ, McDuffie KE, et al. Prediagnostic symptoms of ovarian carcinoma: a case-control study. Gynecol Oncol 2009;114:231-6.
28. Rossing MA, Wicklund KG, Cushing-Haugen KL, et al. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010;102:222-9.
29. Antoniou AC, Rookus M, Andrieu N, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009;18:601-10.
30. Grimbizis GF, Tarlatzis BC. The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2010;24:29-38.
31. La Vecchia C. Oral contraceptives and ovarian cancer: an update, 1998-2004. Eur J Cancer Prev 2006;15:117-24. (Pubitemid 44145596)
32. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:26-34. (Pubitemid 46001033)
33. Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002;94:50-60. (Pubitemid 34082843)
34. Clinicaltrials.gov [Web site]. Phase II double blind randomized trial evaluating the biologic effect of levonorgestrel on the ovarian epithelium in women at high risk for ovarian cancer. (IND#79, 610). Available at http://www.clinicaltrials.gov/ct2/show/NCT00445887?term=GOG+0214&rank=1. Accessed April 12, 2010.
35. Marchetti C, Pisano C, Facchini G, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther 2010;10:47-60.
36. Angioli R, Plotti F, Palaia I, et al. Update on lymphadenectomy in early and advanced ovarian cancer. Curr Opin Obstet Gynecol 2008;20:34-9.
37. Burghardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991;40:103-6.
38. Carnino F, Fuda G, Ciccone G, et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol 1997;65:467-72. (Pubitemid 27255990)
39. Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 2007;17:1238-44. (Pubitemid 350077354)
40. Maggioni A, Benedetti Panici P, Dell'Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006;95:699-704. (Pubitemid 44373484)
41. Aletti GD, Dowdy S, Podratz KC, et al. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 2006;195:1862-8. (Pubitemid 44792638)
42. Chan JK, Munro EG, Cheung MK, et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007;109:12-9. (Pubitemid 46043192)
43. Chan JK, Urban R, Hu JM, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer 2007;96:1817-22. (Pubitemid 46912018)
44. Wimberger P, Lehmann N, Kimmig R, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74. (Pubitemid 46898573)
45. Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560-6. (Pubitemid 40723783)
46. Clinicaltrials.gov [Web site]. Randomized, multicentre trial for lymphadenectomy in ovarian neoplasms. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00712218. Accessed March 28, 2010.
47. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews; 2006; CD005340.
48. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
49. Tewari D, Chunqiao T, Armstrong DK, et al. The clinical-pathologic factors relevant to intraperitoneal chemotherapy in ovarian cancer: An analysis of two Gynecologic Oncology Group trials. J Clin Oncol 2008;26(15 suppl): 304s (abstract 5549).
50. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006;100:27-32. (Pubitemid 41815045)
51. Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 2009;14:683-94.
52. Long K, Malik R, Curtin JP, et al. IP catheter complications and associated risk factors in patients with ovarian cancer. J Clin Oncol 2008;26(15 suppl): 299s (abstract 5525).
53. Gynecologic Oncology Group [Website]. Chemotherapy IP. Educational Materials. Available at: http://www.gog.org/ipchemoed/ipchemoed.html. Accessed March 29, 2010.
54. Clinicaltrials.gov [Web site]. A Phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00993655. Accessed March 28, 2010.
55. Clinicaltrials.gov [Web site]. A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma NCI-supplied agent (s): bevacizumab. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00951496. Accessed March 28, 2010.
56. Krasner CN, Seiden MV, Fuller AF, et al. Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. J Clin Oncol 2007;25(18 suppl): 279s (abstract 5521).
57. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008;68:771-89. (Pubitemid 351550530)
58. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
59. Thigpen T [personal communication].
60. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-25.
61. Hoskins PJ. Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy. J Clin Oncol 2009;27:1355-8.
62. Clinicaltrials.gov [Web site]. A phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (NSC #704865, IND #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosed, previously untreated, suboptimal advanced stage epithelial ovarian, primary peritoneal cancer, or fallopian tube cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00262847. Accessed March 29, 2010.
63. Clinicaltrials.gov [Web site]. ICON7-a randomized, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00483782. Accessed March 29, 2010.
64. Cho KR. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med 2009;133:1775-81.
65. Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep 2008;10:519-23.
66. Mabuchi S, Kawase C, Altomare DA, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009;15:5404-13.
67. Frumovitz M, Schmeler KM, Malpica A, et al. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol 2010;117:491-6.
68. Pectasides D, Pectasides E, Psyrri A, et al. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 2006;11:1089-94. (Pubitemid 44788400)
69. Tsuda H, Ito YM, Ohashi Y, et al. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 2005;11:6880-8. (Pubitemid 41428744)
70. Randomized phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary. Available at: http://www.gcig.igcs.org/ files/JGOG3017-Protocol.pdf. Accessed April 7, 2010.
71. Clinicaltrials.gov [Web site]. A GCIG Intergroup multicenter trial of open label carboplatin and paclitaxel ± bevacizumab compared with oxaliplatin and capecitabine ± bevacizumab as first line chemotherapy in patients with mucinous epithelial ovarian cancer (mEOC). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01081262. Accessed April 7, 2010.
72. Clinicaltrials.gov [Web site]. A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or xyotax (CT 2103) (IND#70177), versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy. Available at: http://www.clinicaltrials.gov/ct/show/NCT00108745. Accessed March 28, 2010.
73. Clinicaltrials.gov [Web site]. A phase III study to evaluate the efficacy and safety of pazopanib monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00866697. Accessed March 29, 2010.
74. Clinicaltrials.gov [Web site]. A double-blind randomized phase II study evaluating the efficacy and safety of sorafenib compared to placebo in ovarian epithelial cancer or primary peritoneal cancer patients who have achieved a complete clinical response after standard platinum/taxane containing chemotherapy. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00791778. Accessed March 29, 2010.
75. Conte PF, Favalli G, Gadducci A, et al. Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT). J Clin Oncol 2007;25(18 suppl): 275s (abstract 5505).
76. De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004;22:2635-42. (Pubitemid 41103751)
77. Markman M, Liu P, Wilczynski S, et al. Survival of ovarian cancer patients treated on SWOG9701/GOG178:12 vs. 3 cycles of monthly single-agent paclitaxel following attainment of a clinically-defined complete response to platinum. J Clin Oncol 2006;24(18 suppl): 257s (abstract 5005).
78. Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006;98:1036-45. (Pubitemid 44288151)
79. Vergote I, van Gorp T, Amant F, et al. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer 2008;18(Suppl 1): 11):11-9. (Pubitemid 351389047)
80. Weinberg LE, Rodriguez G, Hurteau JA. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol 2010;101:334-43.
81. Redman CW, Warwick J, Luesley DM, et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:142-6. (Pubitemid 24195975)
82. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489-97.
83. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
84. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:2873-83. (Pubitemid 47123151)
85. Vergote I, Tropé CG, Amant F, et al. EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube, and peritoneal cancer (OVCA). Paper presented at: the 12th Biennial Meeting of the International Gynecologic Cancer Society; October 25-28, 2008; Bangkok, Thailand. Abstract 1767.
86. Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer - Analysis of prospectively randomized AGO=OVAR/GINECO trials. Paper presented at: the 12th Biennial Meeting of the International Gynecologic Cancer Society; October 25-28, 2008; Bangkok, Thailand. Abstract 437.
87. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22. (Pubitemid 32642183)
88. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
89. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-707. (Pubitemid 46630933)
90. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-9.
91. Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008;26:3176-82.
92. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinumsensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009;19(Suppl 2): S63-7.
93. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107-14.
94. Pujade-Lauraine E, Mahner S, Kaern J, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 2009;27(15 suppl): 279s (abstract LBA5509).
95. Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 2007;8:2293-305. (Pubitemid 350001591)
96. Blackledge G, Lawton F, Redman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989;59:650-3. (Pubitemid 19111764)
97. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36:207-11. (Pubitemid 20061287)
98. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120-5. (Pubitemid 41103725)
99. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
100. Pujade-Lauraine E, Paraiso D, Cure H, et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 2002;21: (abstract 829).
101. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-8. (Pubitemid 27475726)
102. Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;117:324-9.
103. Clinicaltrials.gov [Web site]. A randomised trial of concurrent (with platinum based chemotherapy) and maintenance cediranib in women with platinum sensitive relapsed ovarian cancer. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT00532194. Accessed April 2, 2010.
104. Clinicaltrials.gov [Web site]. A Phase III, multicenter, randomized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovary, primary peritoneal, or fallopian tube carcinoma. Available at: http://www. clinicaltrials.gov/ct2/show/NCT00434642. Accessed April 7, 2010.
105. Clinicaltrials.gov [Web site]. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab (NSC #704865, IND #7921) followed by bevacizumab and secondary cytoreduction surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00565851. Accessed April 7, 2010.
106. Clinicaltrials.gov [Web site]. AURELIA. A multi-center, open-label, randomised, two-arm phase III trial of the effect on progression free survival of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00976911. Accessed April 7, 2010.
107. Clinicaltrials.gov [Web site]. A phase II evaluation of SU11248 (sunitinib malate) (IND #74019, NSC #736511) in the treatment of persistent or recurrent clear cell ovarian carcinoma. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00979992. Accessed April 7, 2010.
108. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-53. (Pubitemid 30027690)
109. Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000;79:344-9.
110. Janicke F, Holscher M, Kuhn W, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129-36.
111. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001;83:504-12. (Pubitemid 33139711)
112. Tay EH, Grant PT, Gebski V, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002;99:1008-13. (Pubitemid 34621223)
113. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004;100:1152-61. (Pubitemid 38325942)
114. Zang RY, Zhang ZY, Li ZT, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 2000;75:24-30.
115. Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007;109:685-91. (Pubitemid 46233229)
116. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106:1933-9. (Pubitemid 43673208)
117. Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 2005;92:1026-32. (Pubitemid 40546664)
118. Clinicaltrials.gov [Web site]. Validation of a score of predictive factors for complete resection in platinum-sensitive recurrent ovarian cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00368420. Accessed April 9, 2010.
119. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006;13:1702-10. (Pubitemid 44951480)
120. Oskay-Oezcelik G, du Bois A, Fasching PA, et al. What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1, 060 patients with ovarian cancer. J Clin Oncol 2009;27(15 suppl): 282s (abstract 5522).
121. Rustin GJ, van der Burg ME. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 2009;27(15 suppl): 5s (abstract 1).
122. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-81.
123. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007;25:2894-901. (Pubitemid 47123153)
124. Markman M. Antiangiogenic drugs in ovarian cancer. Expert Opin Pharmacother 2009;10:2269-77.
125. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71. (Pubitemid 350237599)
126. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6. (Pubitemid 350232248)
127. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
128. Monk BJ, Han E, Josephs-Cowan CA, et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006;102:140-4. (Pubitemid 44056265)
129. Wright JD, Secord AA, Numnum TM, et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer 2008;18:400-6. (Pubitemid 351668295)
130. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25:2902-8. (Pubitemid 47123154)
131. Han ES, Monk BJ. Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 2007;7:1339-45. (Pubitemid 351826900)
132. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007;105:3-6. (Pubitemid 46441477)
133. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2010;28(15 suppl): 5s (abstract LBA1).
134. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study. J Clin Oncol 2007;25(18 suppl): 289s (abstract 5561).
135. Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008;26(15 suppl): 298s (abstract 5521).
136. Matei D, Sill MW, DeGeest K, et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2008;26(15 suppl): 301s (abstract 5537).
137. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-6.
138. Clinicaltrials.gov [Web site]. Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01015118. Accessed April 2010.
139. Welch S, Hirte H, Elit L, et al. CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-A trial of the PMH Phase II Consortium. J Clin Oncol 2007;25(18 suppl): 278s (abstract 5519).
140. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 2007;25(18 suppl): 276s (abstract 5508).
141. Clinicaltrials.gov [Web site]. A multicenter randomized, double-blind, placebocontrolled, parallel-arm study of the effect of intravenous AVE0005 (VEGF Trap) administered every 2 weeks in advanced ovarian cancer patients with recurrent symptomatic malignant ascites. Available at: http://www. clinicaltrials.gov/ct2/show/NCT00327444. Accessed April 5, 2010.
142. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
143. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009;27(suppl): (abstract 5500).
144. Fong PC, Boss DS, Carden CP, et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J Clin Oncol 2008;26(15 suppl): 295s (abstract 5510).
145. Clinicaltrials.gov [Web site]. A phase II, open-label, randomised, comparative, international multicentre study to assess the safety and efficacy of different doses of AZD2281 given orally twice daily versus intravenous liposomal doxorubicin given monthly in patients with advanced BRCA1-or BRCA2-associated ovarian cancer who have failed previous platinum-based chemotherapy. Available at: http://www clinicaltrials.gov/ct2/show/NCT00628251. Accessed April 15, 2010.
146. Clinicaltrials.gov [Web site]. A phase I study of carboplatin/paclitaxel/ CTEP supplied agent bevacizumab (NSC #704865, IND #7921) and CTEP supplied agent ABT-888 (NSC #737664 IND#77840) in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube or primary peritoneal cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00989651. Accessed April 1, 2010.
147. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81. (Pubitemid 39446895)
148. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8. (Pubitemid 40525186)
149. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71.
150. Nakayama K, Nakayama N, Kurman RJ, et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 2006;5:779-85. (Pubitemid 44775134)
151. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004;23:5853-7. (Pubitemid 39093031)
152. Clinicaltrials.gov [Web site]. A phase II evaluation of CCI-779 (temsirolimus, NCI-supplied agent, NSC #683864, IND #61010) in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00429793. Accessed April 10, 2010.
153. Clinicaltrials.gov [Web site]. A phase II randomized, double-blinded evaluation of oral everolimus (RAD001) plus bevacizumab vs. oral placebo plus bevacizumab in the treatment of recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Available at: http://www. clinicaltrials.gov/ct2/show/NCT00886691. Accessed April 10, 2010.
154. Eaves CJ. Manipulating hematopoietic stem cell amplification with Wnt. Nat Immunol 2003;4:511-2. (Pubitemid 36701332)
155. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7. (Pubitemid 46018516)
156. Park JT, Li M, Nakayama K, et al. Notch3 gene amplification in ovarian cancer. Cancer Res 2006;66:6312-8.
157. Hopfer O, Zwahlen D, Fey MF, et al. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 2005;93:709-18. (Pubitemid 41486463)